MYND Life Sciences Inc
CNSX:MYND
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (11.4), the stock would be worth CA$-0.15 (317% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -5.2 | CA$0.07 |
0%
|
| Industry Average | 11.4 | CA$-0.15 |
-317%
|
| Country Average | 14.5 | CA$-0.19 |
-376%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
M
|
MYND Life Sciences Inc
CNSX:MYND
|
1.7m CAD | -5.2 | -1.7 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
309.8B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | 3 537.2 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
102.5B ZAR | 14.4 | 10.6 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
68B USD | -17 989.5 | 38 417.9 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
58.9B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
35.4B CHF | 0 | 0 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
37.6B USD | -737.3 | -3 457.1 | |
| US |
|
Coupang Inc
F:788
|
31.7B EUR | 67.3 | 175.5 | |
| US |
R
|
Reddit Inc
NYSE:RDDT
|
29.2B USD | 60.5 | 55.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10.6 |
| Median | 14.5 |
| 70th Percentile | 20.6 |
| Max | 3 794.4 |
Other Multiples
MYND Life Sciences Inc
Glance View
MYND Life Sciences, Inc. is a neuro-pharmaceutical drug development company. The company is headquartered in Kelowna, British Columbia. The company went IPO on 2021-05-26. The firm is focused on conducting research linking depression and inflammation at the genetic and cellular level to develop a pharmaceutical treatment utilizing compounds found in psychedelics with the initial focus being on psilocybin and its various analogs. The company is working on advancing medicines based on neuro-anti-inflammatory substances through rigorous science and clinical trials with an initial focus on Major Depressive Disorder (MDD). The Company’s lead development program, referred to as the Human Mycogene Modulation program (HMM), is designed to treat neuropsychiatric disorders through the dosing of formulations of psilocybin. The company is evaluating additional indications for its HMM program, including autoimmune disorders (AD) and other MDD conditions.
